28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with resected non-small-cell lung cancer.

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of adults with stage 2 to 3a non-small-cell lung cancer after complete tumour resection whose:

• Tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour cells
• Disease has not progressed after platinum-based adjuvant chemotherapy.

It is recommended only if Roche provides atezolizumab according to the managed access agreement.

Read NICE Technology Appraisal Guidance